Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

TNF Pharmaceuticals, Inc. - Common Stock (NQ:TNFA)

0.4040 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about TNF Pharmaceuticals, Inc. - Common Stock

Tuesday's after hours session: top gainers and losers
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
From TNF Pharmaceuticals, Inc.
Via Business Wire
What's going on in today's after hours session
As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025
From TNF Pharmaceuticals, Inc.
Via Business Wire
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
From TNF Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
From TNF Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference
From TNF Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market
From TNF Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline
From TNF Pharmaceuticals, Inc.
Via Business Wire
TNFA Stock Earnings: TNF Pharmaceuticals Reported Results for Q2 2024
TNF Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.